{{Rsnum
|rsid=868856
|Gene=MOBKL2B
|Chromosome=9
|position=27489253
|Orientation=minus
|GMAF=0.3701
|Gene_s=MOB3B
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 52.2 | 38.1 | 9.7
| HCB | 43.8 | 41.6 | 14.6
| JPT | 61.6 | 33.9 | 4.5
| YRI | 14.3 | 49.0 | 36.7
| ASW | 24.6 | 59.6 | 15.8
| CHB | 43.8 | 41.6 | 14.6
| CHD | 38.0 | 44.4 | 17.6
| GIH | 52.5 | 39.6 | 7.9
| LWK | 17.3 | 50.0 | 32.7
| MEX | 34.5 | 51.7 | 13.8
| MKK | 16.0 | 51.3 | 32.7
| TSI | 48.0 | 44.1 | 7.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs868856
|Name_s=
|Gene_s=MOBKL2B
|Feature=
|Evidence=PubMed ID:18615156
|Annotation=This variant is significantly associated with the efficacy of anti-TNF treatment in rheumatoid arthritis (Adjusted P-value: 0.0000005; OR: 4.9 (1.8, 14.0)). The study is a genome-wide association study using the Illumina HapMap300 SNP chip on 89 RA patients prospectively followed after beginning of anti-TNF therapy.
|Drugs=adalimumab; etanercept; infliximab
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA162928827
}}

{{PMID Auto
|PMID=20423481
|Title=Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs868856
|overall_frequency_n=75
|overall_frequency_d=128
|overall_frequency=0.585938
|n_genomes=46
|n_genomes_annotated=0
|n_haplomes=67
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}